Senores Pharmaceuticals Limited
- Minimum Investment₹14,136
- Price Range₹372 - ₹391
- Issue Size₹582.11 Cr
- Lot Size38 shares
Proceeds of this IPO to be used for
Funding capital expenditure requirements by investment in a subsidiary, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to set up a manufacturing facility for the production of sterile injections in the Atlanta Facility
Repayment/pre-payment, in full or in part, of certain borrowings availed by the company and its subsidiaries, Havix, Ratnatris Pharmaceutical (“Ratnatris”), and Senores Pharmaceuticals Inc. (“SPI”)
Funding the working capital requirements of the company and its subsidiaries, SPI and Ratnatris
Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Strengths & Weaknesses of Senores Pharmaceuticals Limited
US FDA approved facility
The company manufactures products for regulated markets through a US FDA-approved OSD facility in Atlanta, US. The Atlanta facility has a strong regulatory track record and has been audited and approved by the US FDA four times since the commencement of its operations.
Long-term arrangements
The company has entered into long-term marketing arrangements for a period ranging between 5-7 years with major generic pharmaceutical and marketing companies that operate in the regulated markets including Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., and Sun Pharmaceuticals Industries.
Dependent on third party partners
The company's business is dependent on the sale of products through third-party marketing partners and distributors. The loss of one or more marketing partners or distributors or the inability to maintain and increase the number of their arrangements for the marketing and distribution of its products could adversely affect the business, financial conditions, and cash flows.
Dependent on a few customers
The company derives a significant part of its revenue from a few customers. If one or more of such customers choose not to source their requirements from the company, or terminate its contracts or purchase orders, its financial condition and results of operations may be adversely affected.
Geographically concentrated
The company derives a significant portion of its revenue from its operations in the United States. A reduction in demand for its products in these regions could adversely affect the business
Financials
Earnings Per Share
No Data
Balance Sheet
Particulars (In Cr) | Y/Y Change | |
---|---|---|
Total Current Assets | -- | |
Total Non-Current Assets | -- | |
Fixed assets | -- | |
Total assets | -- | |
Total Current Liabilities | -- | |
Total Non-Current Liabilities | -- | |
Total Capital Plus Liabilities | -- | |
Total Shareholder Funds | -- | |
Total Debt to Equity | -- |
Cash Flow
Particulars (In Cr) | Y/Y Change | |
---|---|---|
Cash from Operating Activity | -- | |
Cash from Financing Activities | -- | |
Cash from Investing Activities | -- | |
Net Cash Flow | -- |
About Senores Pharmaceuticals Limited
- PromoterSwapnil Jatinbhai Shah
- PromoterAshokkumar Vijaysinh Barot